ABAviv Barzilai

Aviv Barzilai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aviv Barzilai has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Response to Narrowband Ultraviolet B Phototherapy in Early Mycosis Fungoides Is Associated With Morphometric Histological Characteristics

    by Ilan Vashurin, Gil Goldinger, Lotan Levin, Karin Warshavsky, Felix Pavlotsky, Iris Barshack, Aviv Barzilai

    Background and Objective: Narrowband ultraviolet B phototherapy is an established treatment for mycosis fungoides. Data on the factors that predict treatment efficacy are scarce. This study evaluated the association between morphometry of histological parameters and narrowband ultraviolet B efficacy in patients with early‐stage mycosis fungoides. Patients and Methods: Morphometric analyses of the degree of spongiosis and the number and size of lymphocytes in the epidermis were conducted retrospectively on biopsies from 57 patients with early‐stage mycosis fungoides treated with narrowband ultraviolet B phototherapy. Half of the patients achieved remission after 8 weeks and half did not. Results: TCR monoclonality, larger epidermal lymphocytes, and higher degree of spongiosis were associated with poor response ( p < 0.05) with a sensitivity of 0.82, 0.93, and 0.77, respectively, and a specificity of 0.52, 0.79, and 0.72, respectively. This association was still evident at the end of the phototherapy course. Larger lymphocytes in the epidermis correlated with TCR monoclonality ( p = 0.023). Spongiosis was independent of clonality. Conclusion: Morphometric analysis of histological parameters, such as spongiosis and lymphocyte size, is associated with response to narrowband ultraviolet B phototherapy in patients with early‐stage mycosis fungoides and may serve as markers for selecting appropriate, individualized treatment plans. Incorporating morphometry into biopsy analysis of early‐stage MF may also provide better diagnostic and prognostic accuracy.

  • Open Access

    COVID‐19 Outcomes and Vaccination Response Among Patients With Psoriasis Receiving Biologics

    by Danielle Bar, Felix Pavlotsky, Aviv Barzilai, Sharon Baum

    Background: Biologic therapy in psoriasis raises concerns regarding COVID‐19 infection risk and vaccine response, yet real‐world data remain limited. Objective: To evaluate COVID‐19 infection rates, clinical severity, and vaccination response among biologic‐treated patients with psoriasis during the COVID‐19 pandemic. Methods: This cohort study included 12,306 patients with psoriasis followed at a tertiary medical center between March 2020 and May 2023. Primary outcomes included estimated SARS‐CoV‐2 infection rates, hospitalization, ICU admission, mortality, and a composite severe COVID‐19 outcome (hospitalization, ICU admission, or death). Results: Based on national seroprevalence‐adjusted rates, infection occurred in 673 of 962 biologic‐treated patients (70.0%) and 7657 of 11,344 nonbiologic patients (67.5%) ( p = 0.18). Hospitalization was more frequent among biologic‐treated patients (45.2% vs 25.1%; p < 0.001), while ICU admission rates were comparable (2.6% vs 2.0%; p = 0.41). Mortality was significantly lower in the biologic group (6.3% vs 12.1%; p < 0.001). Conclusions: Biologic therapy in psoriasis was not associated with increased susceptibility to SARS‐CoV‐2 infection or impaired vaccine response.

  • Open Access

    Genetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study

    by Eran Galili, Aviv Barzilai, Atar Lev, Sharon Amit, Ortal Barel, Irit Lubitz, Zeala Gazit, Anna Lyakhovitsky, Raz Somech, Avner Shemer

    Background: Chronic recalcitrant dermatophyte infection (CRDI) remains poorly understood, with limited research on its genetic, immunological and treatment aspects. Objectives: To investigate the genetic and immunological profiles, clinical characteristics and treatment outcomes in otherwise healthy patients with CRDI. Methods: This was a prospective study of patients with isolated superficial dermatophyte infections persisting for > 5 years and refractory to at least three oral antifungal agents. Whole-exome sequencing, interleukin (IL)-17 quantification and lymphocyte subset analysis were performed. Results: Of 5910 patients with superficial cutaneous fungal infections, 11 (10 men; 91%) with a mean (SD) disease duration of 26.4 (8.7) years were included in this study. All patients presented with extensive dermatophytosis, involving a mean (SD) of 5.6 (1.4) skin and nail sites. Immune alterations were identified in 55% (n = 6/11) of the patients, including three with monogenic immunodeficiency mutations (CARD9 and FOXN1), one with acquired immunodeficiency (Good syndrome) and two with isolated IL-17 deficiencies. Most patients (n = 10/11) showed a partial clinical response to continuous oral antifungal therapy, while only one patient remained a complete responder after discontinuing treatment. Conclusions: CRDI is a rare condition in patients with superficial cutaneous fungal infections. Genetic and immunological evaluation for immunodeficiency should be considered in patients with CRDI. Management may require prolonged or lifelong oral antifungal therapy.


  • Open Access

    A high-throughput zebrafish screen identifies novel candidate treatments for Kaposiform Lymphangiomatosis (KLA)

    by Ivan Bassi, Amani Jabali, Naama Farag, Shany Egozi, Noga Moshe, Gil S. Leichner, Polina Geva, Lotan Levin, Aviv Barzilai, Camila Avivi, et al.

    Kaposiform Lymphangiomatosis (KLA) is a rare, aggressive, and incurable disease caused by a somatic activating NRAS mutation (p.Q61R) in lymphatic endothelial cells (LECs). The development of new therapeutic avenues is hampered by the lack of animal models faithfully replicating the clinical manifestations of KLA. Here, we established a novel zebrafish model of KLA by driving conditional expression of the human NRAS mutation in venous and lymphatic ECs. We find that mutant embryos recapitulated clinical features of KLA, including pericardial edema and a dilated thoracic duct, and that the phenotypes were reverted by Trametinib, a MEK inhibitor used for KLA treatment. We further leverage this model in combination with an AI-based high-throughput drug screening platform to search for small compounds selectively reverting the mutant phenotypes and identify Cabozantinib, an FDA-approved tyrosine kinase inhibitor, and GSK690693, a competitive pan-Akt kinase inhibitor, as leading hits. Finally, we test these drugs in cultured cells derived from KLA patient and demonstrate their ability to normalize LEC sprouting and block NRAS downstream pathways, underscoring the potential of GSK690693 and Cabozantinib as potential KLA treatments. Overall, our novel zebrafish model provides a valuable tool for research into the etiology of KLA and for identifying new therapeutic avenues.


  • Primary Melanoma miRNA Trafficking Induces Lymphangiogenesis

    by Gil S. Leichner, Inbal Schweitzer, Shani Dror, Lotan Levin, Polina Geva, Tamar Golan, Laureen Zaremba, Guy Shapira, Roma Parikh, Noam Shomron, et al.


  • Altered RNA Editing in Atopic Dermatitis Highlights the Role of Double-Stranded RNA for Immune Surveillance

    by Miriam Karmon, Eli Kopel, Aviv Barzilai, Polina Geva, Eli Eisenberg, Erez Y. Levanon, Shoshana Greenberger


  • Open Access

    Illness Perception Regarding Early-stage Mycosis Fungoides among Dermatologists: A Multi-centre Cross-sectional Study

    by Oz Segal, Gil Goldzweig, Iris Shapiro Bratt, Sharon Baum, Anna Lyakhovitsky, Aviv Barzilai

    Early-stage mycosis fungoides is a rare cutaneous T-cell lymphoma with a good prognosis. Data regarding patients’ illness perception of mycosis fungoides are accumulating. However, investigating the dermatologists’ viewpoint is also essential, as it shapes the therapeutic relationship and doctor–patient communication. The aim of this study was to investigate the aspects of dermatologists’ illness perception towards early-stage mycosis fungoides and the way they present it to patients. Twenty-five dermatology residents and 55 attending physicians from all Israeli dermatology departments and the community completed the study questionnaires online. Dermatologists viewed mycosis fungoides as a chronic disease, causing a moderate emotional burden. In contrast to previously published data regarding patients’ illness perception, dermatologists demonstrated dominancy in the notion that patients were able to control their disease. Most dermatologists thought that patients perceived mycosis fungoides as an indolent lymphoma that causes anxiety. Dermatologists used a high diversity of themes when presenting mycosis fungoides to patients. The differences between the residents’ and attending physicians’ perceptions were minimal. Dermatologists have a kaleidoscope of views regarding the way they perceive mycosis fungoides, the way they think patients perceive it, and the way they communicate with patients. Maintaining patient-centred communication enables dermatologists to identify these gaps and view mycosis fungoides from their patients’ perspective.


  • Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre

    by Anna Lyakhovitsky, Ido Tzanani, Sarit Gilboa, Oz Segal, Eran Galili, Sharon Baum, Aviv Barzilai

    Background: Hair‐ and scalp‐related disorders (HSRDs) encompass a wide range of conditions that affect people of all ages.Objective: To evaluate the workload and trends in HSRDs at an outpatient dermatological clinic in a tertiary medical centre over a 10‐year period.Methods: Medical records for HSRD visits to the outpatient dermatology clinic at the Sheba Medical Center, an Israeli tertiary care center, were reviewed between 1 January, 2010 and 31 December, 2020.Results: There were 10,396 HSRD visits with a new‐to‐follow‐up visit ratio of 1:1.9. The annual number of HSRD visits, as well as their proportion out of all dermatological outpatient visits, have increased from 295 (1.24%) in 2010 to 1726 (9.44%) in 2020. The patients' mean age was 35.3 years (women 39.5 years, men 28.8 years), age range 1–87 years. Over the decade, there was a growing predominance of women with an average female‐to‐male ratio of 2:1. The winter season accounted for 28.7% of annual visits, followed by the autumn (25.6%), summer (24.3%) and spring (21.4%). The most prevalent HSRDs included androgenetic alopecia (30.6%), alopecia areata (19.3%), telogen effluvium (15.4%), non‐scarring folliculitis (15.4%), seborrheic dermatitis (14.9%), lichen planopilaris (7.1%) and folliculitis decalvans (6.6%). Androgenetic alopecia demonstrated the highest increase over the decade examined (from 17% to 32%).Conclusion: HSRDs account for a significant percentage of visits at a tertiary dermatology outpatient clinic. The number of HSRD visits has increased annually over the past decade. The recent advancement in diagnosis and treatment may account, at least in part, for the growing burden of HSRDs within dermatological ambulatory care.


  • Open Access

    Illness perception, coping, and quality of life in early-stage Mycosis fungoides

    by Oz Segal, Naama Trumper, Felix Pavlotsky, Gil Goldzweig, Aviv Barzilai